Profile and primary treatment outcomes in membranous nephropathy

References

1. 1.↵
   1. Ronco P,
   2. Plaisier E,
   3. Debiec H.

   Advances in membranous nephropathy. J Clin Med 2021; 10: 607.

   OpenUrl
2. 2.↵
   1. Rojas-Rivera J,
   2. Fervenza FC,
   3. Ortiz A.

   Recent clinical trials insights into the treatment of primary membranous nephropathy. Drugs 2022; 82: 109–132.

   OpenUrl
3. 3.↵
   1. Skorecki K,
   2. Chertow GM,
   3. Marsden PA,
   4. Taal MW,
   5. Yu ASL

   1. Pendergraft WF,
   2. Nachman PH,
   3. Jennette JC,
   4. Falk RJ

   . Primary Glomerular Disease. In: Skorecki K, Chertow GM, Marsden PA, Taal MW, Yu ASL. Brenner & Rector’s the Kidney. 10th edition. Philadelphia: Elsevier 2016. pp.1013–1090.
4. 4.↵
   1. Ponticelli C,
   2. Zucchelli P,
   3. Passerini P,
   4. Cagnoli L,
   5. Cesana B,
   6. Pozzi C, et al.

   A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1989; 320: 8–13.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Jha V,
   2. Ganguli A,
   3. Saha TK,
   4. Kohli HS,
   5. Sud K,
   6. Gupta KL, et al.

   A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 2007; 18: 1899–1904.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Rizvi AH,
   2. Naqvi S,
   3. Ahmed R,
   4. Akhter E,
   5. Abbas F,
   6. Mubarak K, et al.

   Clinicopathological profile and prognosis of idiopathic membranous nephropathy in adults: a developing country perspective. Port J Nephrol Hypert 2016; 30: 127–133.

   OpenUrl
7. 7.↵
   1. Van den Brand JA,
   2. van Dijk PR,
   3. Hofstra JM,
   4. Wetzels JF.

   Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy. J Am Soc Nephrol 2014; 25: 150–158.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Ram R,
   2. Guditi S,
   3. Kaligotla Venkata D. A

   10-year follow-up of idiopathic membranous nephropathy patients on steroids and cyclophosphamide: a case series. Ren Fail 2015; 37: 452–455.

   OpenUrl
9. 9.↵
   1. Ramachandran R,
   2. Yadav AK,
   3. Kumar V,
   4. Siva Tez Pinnamaneni V,
   5. Nada R,
   6. Ghosh R, et al.

   Two-year follow-up study of membranous nephropathy treated with tacrolimus and corticosteroids versus cyclical corticosteroids and cyclophosphamide. Kidney Int Rep 2017; 2: 610–616.

   OpenUrl
10. 10.↵
    1. Eriguchi M,
    2. Oka H,
    3. Mizobuchi T,
    4. Kamimura T,
    5. Sugawara K,
    6. Harada A.

    Long-term outcomes of idiopathic membranous nephropathy in Japanese patients treated with low-dose cyclophosphamide and prednisolone. Nephrol Dial Transplant 2009; 24: 3082–3088.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Cui W,
    2. Lu X,
    3. Min X,
    4. Liu M,
    5. Guan S,
    6. Wang Y, et al.

    Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy. Braz J Med Biol Res 2017; 50: e5976.

    OpenUrl
12. 12.↵
    1. Qin HZ,
    2. Liu L,
    3. Liang SS,
    4. Shi JS,
    5. Zheng CX,
    6. Hou Q, et al.

    Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients. BMC Nephrol 2017; 18: 2.

    OpenUrl
13. 13.↵
    1. Liang Q,
    2. Li H,
    3. Xie X,
    4. Qu F,
    5. Li X,
    6. Chen J.

    The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy. Ren Fail 2017; 39: 512–518.

    OpenUrl
14. 14.↵
    1. Ruggenenti P,
    2. Cravedi P,
    3. Chianca A,
    4. Perna A,
    5. Ruggiero B,
    6. Gaspari F, et al.

    Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 2012; 23: 1416–1425.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Teisseyre M,
    2. Cremoni M,
    3. Boyer-Suavet S,
    4. Crepin T,
    5. Benzaken S,
    6. Zorzi K, et al.

    Rituximab immunomonitoring predicts remission in membranous nephropathy. Front Immunol 2021; 12: 738788.

    OpenUrl
16. 16.↵
    1. Cattran DC,
    2. Kim ED,
    3. Reich H,
    4. Hladunewich M,
    5. Kim SJ.

    Membranous nephropathy: quantifying remission duration on outcome. J Am Soc Nephrol 2017; 28: 995–1003.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Dahan K,
    2. Debiec H,
    3. Plaisier E,
    4. Cachanado M,
    5. Rousseau A,
    6. Wakselman L, et al.

    Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J Am Soc Nephrol 2017; 28: 348–358.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Ou JY,
    2. Chen YW,
    3. Li TL,
    4. Shan HZ,
    5. Cui S,
    6. Lai JJ, et al.

    Evaluation of efficacy of rituximab for membranous nephropathy: a systematic review and meta-analysis of 11 studies. Nephrol Ther 2022; 18: 104–112.

    OpenUrl